Sanofi revenue by segment 2014-2024
Published by
In 2024, French pharmaceutical company Sanofi generated approximately 41 billion euros through its biopharmaceutical segment. In 2023, Sanofi’s consumer healthcare segment earned the company about 5.2 billion euros in that year. As of early 2025, due to several restructuring measures, Sanofi consists only of the biopharma segment.
Sanofi’s top products
Sanofi develops various pharmaceutical products, including Dupixent and Lantus. Lantus has been one of the company’s top products for many years. In 2024, this long-acting insulin, used to treat diabetes, generated some 1.6 billion euros.
Top U.S. drugs
Based on sales numbers over the last years, Humira is by far the top prescription drug in the United States. Before 2023, the drug generated around 20 billion U.S. dollars in the United States per year. Among the country’s most prescribed medicines, however, are atorvastatin, lisinopril, and levothyroxine.
